

DAFTAR PUSTAKA

- Abbasinazari, M., Farsad, B. F., Dabagh, A., & Bakshandeh, H. (2016). Evaluation of time in therapeutic range (TTR) in patients with non-valvular atrial fibrillation receiving treatment with warfarin in Tehran, Iran: A cross-sectional study. *Journal of Clinical and Diagnostic Research*, *10*(9), FC04–FC06. <https://doi.org/10.7860/JCDR/2016/21955.8457>
- Akamatsu, H., Nakagawa, H., Matsumaru, I., Hashizume, J., Harasawa, H., Kodama, Y., Miura, T., & Ohyama, K. (2023). Effects of changing the timing of warfarin administration in combination with fluconazole on prolongation of the PT-INR: a case report. *Journal of Pharmaceutical Health Care and Sciences*, *9*(1). <https://doi.org/10.1186/s40780-023-00279-w>
- Al-Momany, N. H., Makahleh, Z. M., Al-Omari, N. A., Al-Sarayreh, H. A., & Momani, R. O. (2019). Analysis of Factors That Interrupt With INR Control in the First Anticoagulation Clinic Monitoring Jordanian Patients. *Clinical and Applied Thrombosis/Hemostasis*, *25*. <https://doi.org/10.1177/1076029619870252>
- Alshammari, A., Altuwayjiri, A., Alshaharani, Z., Bustami, R., & Almodaimegh, H. S. (2020). Warfarin Dosing Requirement According to Body Mass Index. *Cureus*. <https://doi.org/10.7759/cureus.11047>
- Anderson, F. A., & Spencer, F. A. (2003). Risk factors for venous thromboembolism. In *Circulation* (Vol. 107, Issue SUPPL. 23). <https://doi.org/10.1161/01.CIR.0000078469.07362.E6>
- Arch Intern Med. (1994). Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation Analysis of Pooled Data From Five Randomized Controlled Trials. *Arch Intern Med*, *154*, 1449–1457. <https://doi.org/10.1001/archinte.1994.00420130036007>
- Barnes, G. D. (2020). *Combining antiplatelet and anticoagulant therapy in cardiovascular disease*. <https://doi.org/10.1182/hematology.2020000151>.
- Bonde, A. N., Lip, G. Y. H., Kamper, A. L., Fosbøl, E. L., Staerk, L., Carlson, N., Torp-Pedersen, C., Gislason, G., & Olesen, J. B. (2016). Renal function and the risk of stroke and bleeding in patients with atrial fibrillation: An observational cohort study. *Stroke*, *47*(11), 2707–2713. <https://doi.org/10.1161/STROKEAHA.116.014422>
- BRIDGE Study Investigators. (2012). Bridging anticoagulation: is it needed when warfarin is interrupted around the time of a surgery or procedure? In *Circulation* (Vol. 125, Issue 12). <https://doi.org/10.1161/CIRCULATIONAHA.111.084517>
- Brieger, D., Amerena, J., Attia, J., Bajorek, B., Chan, K. H., Connell, C., Freedman, B., Ferguson, C., Hall, T., Haqqani, H., Hendriks, J., Hespe, C., Hung, J., Kalman, J. M., Sanders, P., Worthington, J., Yan, T. D., &

- Zwar, N. (2018). National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. *Heart Lung and Circulation*, 27(10), 1209–1266. <https://doi.org/10.1016/j.hlc.2018.06.1043>
- Brunton, L. L., Lazo, J. S., & Parker, K. L. (2006). *Goodman & Gilman's The Pharmacological Basis of Therapeutics* (11th ed.). McGraw-Hill.
- Bungard, T. J., Yakiwchuk, E., Foisy, M., & Brocklebank, C. (2011). *Drug interactions involving warfarin: Practice tool and practical management tips*. 144(1).
- Caldeira, D., Costa, J., Barra, M., Pinto, F. J., & Ferreira, J. J. (2015). How safe is acetaminophen use in patients treated with vitamin K antagonists? A systematic review and meta-analysis. *Thrombosis Research*, 135(1), 58–61. <https://doi.org/10.1016/j.thromres.2014.10.011>
- Carlin, S., & Eikelboom, J. (2022). Advances in anticoagulation: Patients with bioprosthetic heart valves. *Cardiovascular Research*, 118(3), E26–E28. <https://doi.org/10.1093/cvr/cvab360>
- Chrisholm-Burns, M. A., Schwinghammer, T. L., Malone, P. M., Kolesar, J. M., Bookstaver, P. B., & Lee, K. C. (2019). *Pharmacotherapy Principles & Practice* (5th ed.). McGraw-Hill Education.
- Costello, B. T., Sprung, K., & Coulter, S. A. (2017). The rise and fall of estrogen therapy: Is testosterone for “menopause” next? In *Texas Heart Institute Journal* (Vol. 44, Issue 5, pp. 338–340). Texas Heart Institute. <https://doi.org/10.14503/THIJ-17-6360>
- Dean, L. (2012). *Warfarin Therapy and the Genotypes CYP2C9 and VKORC1*. <http://www.warfarindosing.org>
- Di Minno, A., Frigerio, B., Spadarella, G., Ravani, A., Sansaro, D., Amato, M., Kitzmiller, J. P., Pepi, M., Tremoli, E., & Baldassarre, D. (2017). Old and new oral anticoagulants: Food, herbal medicines and drug interactions. In *Blood Reviews* (Vol. 31, Issue 4, pp. 193–203). Churchill Livingstone. <https://doi.org/10.1016/j.blre.2017.02.001>
- Ebrahim, I., Bryer, A., Cohen, K., Mouton, J. P., Msemburi, W., & Blockman, M. (2018). Poor anticoagulation control in patients taking warfarin at a tertiary and district-level prothrombin clinic in Cape Town, South Africa. *South African Medical Journal*, 108(6), 490–494. <https://doi.org/10.7196/SAMJ.2018.v108i6.13062>
- Efird, L. M., Mishkin, D. S., Berlowitz, D. R., Ash, A. S., Hylek, E. M., Ozonoff, A., Reisman, J. I., Zhao, S., Jasuja, G. K., & Rose, A. J. (2014). Stratifying the risks of oral anticoagulation in patients with liver disease. *Circulation: Cardiovascular Quality and Outcomes*, 7(3), 461–467. <https://doi.org/10.1161/CIRCOUTCOMES.113.000817>
- Eikelboom, J. W., & Hirsh, J. (2007). Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. *Journal of Thrombosis and Haemostasis, Suppl. 1*, 255–263. <https://doi.org/10.1111/j.1538-7836.2007.02499.x>

- Fahmi, A. M., Abdelsamad, O., & Elewa, H. (2016). Rifampin-warfarin interaction in a mitral valve replacement patient receiving rifampin for infective endocarditis: a case report. *SpringerPlus*, 5(1), 1–5. <https://doi.org/10.1186/s40064-015-1653-8>
- Formularium Nasional 2023. (2023). *Daftar Perubahan Fornas 2021 (Fornas 2023)*.
- Friberg, L., Rosenqvist, M., & Lip, G. Y. H. (2012). Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. *European Heart Journal*, 33, 1500–1510. <https://doi.org/https://doi.org/10.1093/eurheartj/ehr488>
- Furdiyanti, N. H., Pramantara, I. D. P., & Wahyono, D. (2014). EVALUASI DOSIS WARFARIN DAN HASIL TERAPINYA PADA PASIEN RAWAT JALAN. *Jurnal Manajemen Dan Pelayanan Farmasi*, 175–179.
- Garcia, D., Regan, S., Crowther, M., Hughes, R. A., & Hylek, E. M. (2005). Warfarin Maintenance Dosing Patterns in Clinical Practice. *CHEST*, 127(6), 2049–2056.
- Gomes, T., Mamdani, M. M., Holbrook, A. M., Paterson, J. M., Hellings, C., & Juurlink, D. N. (2013). Rates of hemorrhage during warfarin therapy for atrial fibrillation. *CMAJ. Canadian Medical Association Journal*, 185(2). <https://doi.org/10.1503/cmaj.121218>
- Hart, R. G., Pearce, Lesly. A., & Aguilar, M. I. (2007). Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. *Annals of Internal Medicine*, 146. <https://www.acpjournals.org/doi/10.7326/0003-4819-146-12-200706190-00007>
- Hirsh, J., Fuster, V., Ansell, J., & Halperin, J. L. (2003). American Heart Association/American College of Cardiology foundation guide to warfarin therapy. In *Journal of the American College of Cardiology* (Vol. 41, Issue 9, pp. 1633–1652). Elsevier Inc. [https://doi.org/10.1016/S0735-1097\(03\)00416-9](https://doi.org/10.1016/S0735-1097(03)00416-9)
- Islam, M. M., Ademoğlu, E., Uygun, C., Delipoyraz, M., Satıcı, M. O., Aksel, G., Eroğlu, S. E., & Özdemir, S. (2023). Comparison of the effects of different treatment protocols on mortality in patients presenting with an INR \geq 10 due to warfarin-associated over-anticoagulation. *African Journal of Emergency Medicine*, 13(1), 8–14. <https://doi.org/10.1016/j.afjem.2022.12.001>
- Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., ... Van Wagoner, D. R. (2024). 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. In *Circulation* (Vol. 149,

- Issue 1, pp. E1–E156). Lippincott Williams and Wilkins. <https://doi.org/10.1161/CIR.0000000000001193>
- Katzung, B. G. (2017). *Basic & Clinical Pharmacology* (14th ed.). McGraw Gill .
- Kawai, M., Harada, M., Motoike, Y., Koshikawa, M., Ichikawa, T., Watanabe, E., & Ozaki, Y. (2019). Impact of serum albumin levels on suprathreshold PT-INR control and bleeding risk in atrial fibrillation patients on warfarin: A prospective cohort study. *IJC Heart and Vasculature*, 22, 111–116. <https://doi.org/10.1016/j.ijcha.2019.01.002>
- Kemkes BKKP. (2025). *Program Jaminan Kesehatan Nasional (JKN)*. <https://www.badankebijakan.kemkes.go.id/program-jaminan-kesehatan-nasional-jkn/>
- Khan, T. M., Patel, R., & Siddiqui, A. H. (2023). *Furosemide*. National Library of Medicine. <https://www.ncbi.nlm.nih.gov/books/NBK499921/>
- Khoury, G., & Sheikh-Taha, M. (2014). Effect of age and sex on warfarin dosing. *Clinical Pharmacology: Advances and Applications*, 6(1), 103–106. <https://doi.org/10.2147/CPAA.S66776>
- Lee, S. L., Ong, T. J., Mazlan-Kepli, W., Mageswaran, A., Tan, K. H., Abd-Malek, A. M., & Cronshaw, R. (2021). Patients' time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. *World Journal of Cardiology*, 13(9), 483–492. <https://doi.org/10.4330/WJC.V13.I9.483>
- Leopoulou, M., Theofilis, P., Kordalis, A., Papageorgiou, N., Sagris, M., Oikonomou, E., & Tousoulis, D. (2023). Diabetes mellitus and atrial fibrillation—from pathophysiology to treatment. *World Journal of Diabetes*, 14(5), 512–527. <https://doi.org/10.4239/wjd.v14.i5.512>
- Lim, G. B. (2017). Warfarin: from rat poison to clinical use. *Nature Reviews Cardiology*. <https://doi.org/10.1038/nrcardio.2017.172>
- Limdi, N. A., Beasley, T. M., Baird, M. F., Goldstein, J. A., McGwin, G., Arnett, D. K., Acton, R. T., & Allon, M. (2009). Kidney Function Influences Warfarin Responsiveness and Hemorrhagic Complications. *Journal of the American Society of Nephrology*, 20(4), 912–921. <https://doi.org/10.1681/ASN.2008070802>
- Lwanga, S. Kaggwa., & Lemeshow, Stanley. (1991/1995). *Sample size determination in health studies: a practical manual*. World Health Organization.
- Mack, C. A., Lau, C., & Girardi, L. N. (2024). There is still no alternative to warfarin for mechanical valves: It remains the most effective anticoagulant. In *Journal of Thoracic and Cardiovascular Surgery*. Elsevier Inc. <https://doi.org/10.1016/j.jtcvs.2024.07.011>
- Martins, M. A., Reis, A. M., Sales, M. F., Nobre, V., Ribeiro, D. D., Rocha, M. O., & Ribeiro, A. L. (2013). *Rifampicin-warfarin interaction leading to macroscopic hematuria: a case report and review of the literature*. <http://www.biomedcentral.com/2050-6511/14/27>
- Megawati, S., Lestari, T., & Setyani, W. L. (2019a). Evaluasi Penggunaan Warfarin Oral Terhadap Nilai INR Pasien Jantung Rawat Jalan RSU

- Kabupaten Tangerang 2018. *Jurnal Farmagazine*, 6(2), 10. <https://doi.org/10.47653/farm.v6i2.140>
- Megawati, S., Lestari, T., & Setyani, W. L. (2019b). Evaluasi Penggunaan Warfarin Oral Terhadap Nilai INR Pasien Jantung Rawat Jalan RSU Kabupaten Tangerang 2018. *Jurnal Farmagazine*, 6(2), 10. <https://doi.org/10.47653/farm.v6i2.140>
- Mende, J., Rahmawati, F., & Puspitasari, I. (2022). Keamanan Penggunaan Antikoagulan pada Pasien Rawat Inap Stroke Iskemik dengan Atrial Fibrilasi. *JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)*, 12(3), 176. <https://doi.org/10.22146/jmpf.74893>
- Mozayani, A., & Raymon, L. P. (2004). *Handbook of Drug Interactions: A Clinical and Forensic Guide*. Humana Press.
- Mueller, J. A., Patel, T., Halawa, A., Dumitrascu, A., & Dawson, N. L. (2014). Warfarin Dosing and Body Mass Index. *Annals of Pharmacotherapy*, 48(5), 584–588. <https://doi.org/10.1177/1060028013517541>
- Nakamura, M., Tamaru, S., Hirooka, S., Hirayama, A., Tsuji, A., Hirata, M., Munemasa, M., Nakagawa, I., Toshima, M., Shimokawa, H., Nishimura, Y., Ogura, T., Yamamoto, T., Satokawa, H., Obayashi, T., & Yamada, N. (2024). Efficacy and Safety of Warfarin for the Treatment of Venous Thromboembolism — A Multicenter Prospective Observational Cohort Study in Japan (AKAFUJI Study) —. *Circulation Journal*, 88(3), 359–368. <https://doi.org/10.1253/circj.CJ-23-0158>
- NCBI. (2024). *PubChem Compound Summary for CID 54678486, Warfarin*.
- Ningrum, V. DA, Dyah Widyastuti, I., Sufriyanto Yusuf, B., & Dullah, W. (2020). Senior Clinical Pharmacist at Sleman Regional Public Hospital, Sleman, Daerah Istimewa Yogyakarta, Indonesia 55514 3. Senior Clinical Pharmacist at Bethesda Hospital. In *RESEARCH ARTICLE Indonesian Journal of Pharmacy Indonesian J Pharm* (Vol. 31, Issue 3).
- Octasari, P. M., & Silvianingsih, N. (2022). KESESUAIAN NILAI INR (INTERNATIONAL NORMALIZED RATIO) PASIEN KARDIOVASKULER DENGAN TERAPI WARFARIN DI POLI SPESIALIS JANTUNG RS ROEMANI MUHAMMADIYAH SEMARANG. *Cendekia Journal of Pharmacy*, 6(1). <http://cjp.jurnal.stikescendekiautamakudus.ac.id>
- O'Reilly, R. A. (1987). *Warfarin Metabolism and Drug-Drug Interactions* (S. Wessler, C. G. Becker, & Y. Nemerson, Eds.). Springer.
- Ozturk, M., Ipekci, A., Kiyak, S. K., Akdeniz, Y. S., Aydin, Y., Ikizceli, I., & Sogut, O. (2019). Bleeding Complications in Warfarin-Treated Patients Admitted to the Emergency Department. *Journal of Clinical Medicine Research*, 11(2), 106–113. <https://doi.org/10.14740/jocmr3669>
- Pastori, D., Gazzaniga, G., Farcomeni, A., Bucci, T., Menichelli, D., Franchino, G., Pani, A., Violi, F., Pignatelli, P., Fauchier, L., & Lip, G. Y. H. (2023). Venous Thromboembolism in Patients With Atrial

- Fibrillation: A Systematic Review and Meta-Analysis of 4,170,027 Patients. *JACC: Advances*, 2(7). <https://doi.org/10.1016/j.jacadv.2023.100555>
- PERKI. (2019). PEDOMAN TATA LAKSANA FIBRILASI ATRIUM NONVALVULAR. *Perhimpunan Dokter Spesialis Kardiovaskular Indonesia*. www.transmedicalinstitute.com
- Praxedes, M. F. S., Martins, M. A. P., Mourão, A. O. M., Gomes, K. B., Reis, E. A., Souza, R. P., Campos, E. I. F., Ribeiro, D. D., & Rocha, M. O. C. (2020). Non-genetic factors and polymorphisms in genes CYP2C9 and VKORC1: predictive algorithms for TTR in Brazilian patients on warfarin. *European Journal of Clinical Pharmacology*, 76(2), 199–209. <https://doi.org/10.1007/s00228-019-02772-4>
- Putriana, N. A., Rusdiana, T., Rostinawati, T., Akbar, M. R., & Destiani, D. P. (2022). Evaluation of adverse drug reaction in patients warfarin therapy. *Journal of Advanced Pharmaceutical Technology and Research*, 13(4), 291–295. https://doi.org/10.4103/japtr.japtr_439_22
- Rahmawati, F., Aulia, I. A. A., & Pramantara, I. D. P. (2022). Profil Klinis Pasien Pengguna Warfarin Pada Poli Jantung RSUD Dr. Soeselo Kabupaten Tegal. *Majalah Farmaseutik*, 18(2). <https://doi.org/10.22146/farmaseutik.v1i1.62470>
- Rahmayanti, S. U., & Muhtadi, A. (2018). Review Jurnal: Interaksi Warfarin dan Herbal untuk Meminimalkan Kejadian Adverse Drug Reaction (ADR). *Farmaka*, 16(2).
- Rodgers, J. L., Jones, J., Bolleddu, S. I., Vanthenapalli, S., Rodgers, L. E., Shah, K., Karia, K., & Panguluri, S. K. (2019). Cardiovascular risks associated with gender and aging. In *Journal of Cardiovascular Development and Disease* (Vol. 6, Issue 2). MDPI. <https://doi.org/10.3390/jcdd6020019>
- Shams, P., Malik, A., & Chhabra, L. (2025, February 26). *Heart Failure (Congestive Heart Failure)*. National Library of Medicine. <https://www.ncbi.nlm.nih.gov/books/NBK430873/>
- Shendre, A., Parmar, G. M., Dillon, C., Beasley, T. M., & Limdi, N. A. (2018). Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. *Pharmacotherapy*, 38(6), 588–596. <https://doi.org/10.1002/phar.2089>
- Shikdar, S., Vashisht, R., Zubair, M., & Bhattacharya, P. T. (2025, February 14). *International Normalized Ratio: Assessment, Monitoring, and Clinical Implications*. National Library of Medicine. <https://www.ncbi.nlm.nih.gov/books/NBK507707/>
- Shirayama, T., Shiraishi, H., Kuroyanagi, A., Hamaoka, T., Imai, M., & Kojima, A. (2014). Interaction between Warfarin and Proton Pump Inhibitors. *International Journal of Clinical Medicine*, 05(14), 836–843. <https://doi.org/10.4236/ijcm.2014.514112>
- Shrestha, S., Bhattarai, B., Ghimire, A., Karmacharya, Y., Khanal, S., & Shahukhal, S. (2020). Impact of Pharmacists' Counseling in Patients' Knowledge of Warfarin in a Tertiary Care Cardiac Centre: A

- Prospective Randomized Controlled Study. *Indian Journal of Pharmacy Practice*, 13(2), 166–173. <https://doi.org/10.5530/ijopp.13.2.26>
- Singer, D. E., Hughes, R. A., Gress, D. R., Sheehan, M. A., Oertel, L. B., Maraventano, S. W., Blewett, D. R., Rosner, B., & Kistler, J. P. (1990). The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial Fibrillation. *The New England Journal of Medicine*, 323, 1505–1511.
- Snipelisky, D., & Kusumoto. (2013). Current strategies to minimize the bleeding risk of warfarin. *Journal of Blood Medicine*, 89. <https://doi.org/10.2147/jbm.s41404>
- Sterne, J. A. C., Bodialia, P. N., Bryden, P. A., Davies, P. A., López-López, J. A., Okoli, G. N., Thom, H. H. Z., Caldwell, D. M., Dias, S., Eaton, D., Higgins, J. P. T., Hollingworth, W., Salisbury, C., Savović, J., Sofat, R., Stephens-Boal, A., Welton, N. J., & Hingorani, A. D. (2017). Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: Systematic review, network meta-analysis and cost-effectiveness analysis. In *Health Technology Assessment* (Vol. 21, Issue 9, pp. 1–385). NIHR Journals Library. <https://doi.org/10.3310/hta21090>
- Süfling, L., Greinert, D., & Girndt, M. (2022). Risk of overanticoagulation during acute kidney injury in patients treated with vitamin K antagonists. *Nephrology Dialysis Transplantation*, 37(4), 681–686. <https://doi.org/10.1093/ndt/gfab008>
- Sun, S., Wang, M., Su, L., Li, J., Li, H., & Gu, D. (2006). Study on warfarin plasma concentration and its correlation with international normalized ratio. *Journal of Pharmaceutical and Biomedical Analysis*, 42(2), 218–222. <https://doi.org/10.1016/j.jpba.2006.03.019>
- Tadesse, T. A., Gebremedhin, A., Yadeta, D., Chelkeba, L., & Fenta, T. G. (2024). Comparison of anticoagulation control and outcomes between usual medical care and pharmacist-led anticoagulation service in ambulatory patients taking warfarin at tertiary hospital in Ethiopia: a quasi-experimental study. *Journal of Pharmaceutical Health Care and Sciences*, 10(1). <https://doi.org/10.1186/s40780-024-00355-9>
- Takase, T., Ikesue, H., Tohi, M., Ueta, H., Mima, H., Koyama, T., & Hashida, T. (2018). Interaction between warfarin and short-term intravenous amiodarone in intensive care unit patients after cardiac surgery. *Journal of Pharmaceutical Health Care and Sciences*, 4(1). <https://doi.org/10.1186/s40780-018-0110-6>
- Thijssen, H., Soute, B., Vervoort, L., & Claessens, J. (2004). Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. *Thrombosis and Haemostasis*, 92(04), 797–802. <https://doi.org/10.1160/TH04-02-0109>
- UpToDate. (2025). *Clinical characteristics comprising the HAS-BLED bleeding risk score.*

- UpToDate Lexidrug. (2025a). *Interaction Monograph: Warfarin-Alteplase*. <https://online.lexi.com/lco/action/interact>
- UpToDate Lexidrug. (2025b). *Interaction Monograph (Warfarin-Furosemide)*. <https://online.lexi.com/lco/action/interact>
- UpToDate Lexidrug. (2025c). *Interaction Monograph: Warfarin-Omeprazole*. <https://online.lexi.com/lco/action/interact>
- UpToDate Lexidrug. (2025d). *Interaction Monograph: Warfarin-Phytonadione*. <https://online.lexi.com/lco/action/interact>
- UpToDate Lexidrug. (2025e). *Warfarin*. https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4668998?cesid=7LT2AJEwldW&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dwarfarin%26t%3Dname%26acs%3Dfalse%26acq%3Dwarfarin
- Uyungül, E., Ayrik, C., Narci, H., Erdoğan, S., Toker, I., Demir, F., & Karaaslan, U. (2014). Determining risk factors of bleeding in patients on warfarin treatment. *Advances in Hematology*, 2014. <https://doi.org/10.1155/2014/369084>
- Verdecchia, P., Angeli, F., & Reboldi, G. (2018). Hypertension and atrial fibrillation: Doubts and certainties from basic and clinical studies. In *Circulation Research* (Vol. 122, Issue 2, pp. 352–368). Lippincott Williams and Wilkins. <https://doi.org/10.1161/CIRCRESAHA.117.311402>
- Villa Zapata, L., Hansten, P. D., Panic, J., Horn, J. R., Boyce, R. D., Gephart, S., Subbian, V., Romero, A., & Malone, D. C. (2020). Risk of Bleeding with Exposure to Warfarin and Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review and Meta-Analysis. *Thrombosis and Haemostasis*, 120(7), 1066–1074. <https://doi.org/10.1055/s-0040-1710592>
- Waheed, S. M., Kudaravalli, P., & Hotwagner, D. T. (2023, January 19). *Deep Vein Thrombosis*. National Library of Medicine. <https://www.ncbi.nlm.nih.gov/books/NBK507708/>
- Wang, M., Zeraatkar, D., Obeda, M., Lee, M., Garcia, C., Nguyen, L., Agarwal, A., Al-Shalabi, F., Benipal, H., Ahmad, A., Abbas, M., Vidug, K., & Holbrook, A. (2021). Drug–drug interactions with warfarin: A systematic review and meta-analysis. In *British Journal of Clinical Pharmacology* (Vol. 87, Issue 11, pp. 4051–4100). John Wiley and Sons Inc. <https://doi.org/10.1111/bcp.14833>
- Watson, T., Shantsila, E., & Lip, G. Y. (2009). Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. In *The Lancet* (Vol. 373, Issue 9658, pp. 155–166). Elsevier B.V. [https://doi.org/10.1016/S0140-6736\(09\)60040-4](https://doi.org/10.1016/S0140-6736(09)60040-4)
- Yamagishi, S. I. (2019). Concerns about clinical efficacy and safety of warfarin in diabetic patients with atrial fibrillation. In *Cardiovascular Diabetology* (Vol. 18, Issue 1). BioMed Central Ltd. <https://doi.org/10.1186/s12933-019-0818-0>
- Yong, J. W., Yang, L. X., Ohene, B. E., Zhou, Y. J., & Wang, Z. J. (2017). Periprocedural heparin bridging in patients receiving oral anticoagulation: A systematic review and meta-analysis. *BMC*

Cardiovascular Disorders, 17(1). <https://doi.org/10.1186/s12872-017-0719-7>

Yu, M. A., Bostwick, J. R., & Hallman, I. S. (2011). Warfarin Drug Interactions: Strategies to Minimize Adverse Drug Events The Journal for Nurse Practitioners-JNP 507. In 506 *The Journal for Nurse Practitioners-JNP* (Vol. 7, Issue 6). www.npjjournal.org